VEGF reflects on itself Tim Fulmer doi:10.1038/scibx.2012.943 North American researchers have chemically synthesized a d-protein ligand that blocked the binding of VEGF to its receptor in vitro. Reflexion has licensed the compound and will optimize it further before doing head-to-head comparisons versus Lucentis and Avastin in animal models of AMD. Full Text | PDF
This is (a diagnostic) spinal tap Michael J. Haas doi:10.1038/scibx.2012.944 A team led by KineMed has shown that measuring the kinetics of CNS proteins in cerebrospinal fluid could help diagnose Parkinson's disease and amyotrophic lateral sclerosis. The company is now exploring the utility of the approach to diagnose multiple neurodegenerative diseases and to monitor treatment responses. Full Text | PDF
Cracking ENCODE Lev Osherovich doi:10.1038/scibx.2012.945 ENCODE, a massive effort to characterize the functional elements of the human genome, went public with its findings last week. For industry, the data are likely to spark a re-examination of genomewide association study results. Companies best positioned to take rapid advantage of the findings are those with knockdown technologies able to screen for biological effects of genes the consortium flagged as key disease players. Full Text | PDF
Probing for a point-of-care TB test Kai-Jye Lou doi:10.1038/scibx.2012.946 Researchers at Stanford University and Texas A&M University have synthesized highly sensitive class A β-lactamase–specific fluorogenic probes that could enable the development of a fast and simple point-of-care diagnostic for tuberculosis. Global BioDiagnostics has in-licensed the technology. Full Text | PDF
p38 Mitogen-activated protein kinase (p38 MAPK; MAPK14) doi:10.1038/scibx.2012.947 In vitro and rat studies identified a p38 MAPK inhibitor that could help treat autoimmune diseases. Full Text | PDF
Core-binding factor β-subunit (CBFB; CBFβ); runt-related transcription factor 1 (RUNX1) doi:10.1038/scibx.2012.948 In vitro and mouse studies suggest inhibiting the interaction between RUNX1 and CBFβ could help treat core-binding factor leukemias, which have mutations that affect RUNX1 or CBFβ and account for about 24% of adult AML and 25% of pediatric ALL cases. Full Text | PDF
R-Spondin 2 (RSPO2); RSPO3 doi:10.1038/scibx.2012.949 Human genomic studies suggest antagonizing RSPO2 and RSPO3 gene fusion proteins could be useful for treating colorectal cancer. Full Text | PDF
Multiple endocrine neoplasia I (MEN1; menin) doi:10.1038/scibx.2012.950 Mouse studies suggest adenovirus-mediated MEN1 gene replacement therapy could help treat pituitary tumors in multiple endocrine neoplasia type 1, an autosomal dominant disorder characterized by neuroendocrine tumors. Full Text | PDF
Unknown doi:10.1038/scibx.2012.951 Rat studies suggest antidiabetic prodrugs engineered to release nitric oxide (NO) could reduce cardiovascular risks associated with treatment. Full Text | PDF
ATPase Ca++ transporting plasma membrane 4 (ATP2B4; PMCA4); MARVEL domain containing 3 (MARVELD3) doi:10.1038/scibx.2012.952 Genomewide association studies identified two loci associated with risk of severe malaria that could become drug targets. Full Text | PDF
β-Amyloid 42; prion protein (PRNP; PrP; CD230) doi:10.1038/scibx.2012.953 Cell culture studies suggest soluble PrP could help treat AD. Full Text | PDF
c-Jun N-terminal kinase 3 (JNK3; MAPK10); β-amyloid 42 doi:10.1038/scibx.2012.954 In vitro and mouse studies suggest JNK3 inhibition could help treat AD. Full Text | PDF
Meprin Aβ (MEP1B) doi:10.1038/scibx.2012.955 In vitro studies suggest inhibiting MEP1B could help treat AD. Full Text | PDF
Huntingtin (HTT) doi:10.1038/scibx.2012.956 In vitro and mouse studies suggest allele-selective single-strand small interfering RNA (ss-siRNA) could help treat HD. Full Text | PDF
Amyloid precursor protein (APP); chromogranin B (CHGB); neuregulin 1 (NRG1); α-synuclein (SNCA) doi:10.1038/scibx.2012.957 Mouse and human studies suggest measuring the transport rates of CNS proteins into and out of cerebrospinal fluid (CSF) could help diagnose PD and ALS. Full Text | PDF
Calcium channel voltage-dependent N type-α 1B subunit (CACNA1B; CaV2.2); collapsin response mediator protein-2 (DPYSL2; CRMP-2) doi:10.1038/scibx.2012.958 In vitro and rat studies suggest inhibiting the interaction between CaV2. Full Text | PDF
Neuronal pentraxin 1 (NPTX1; NP1) doi:10.1038/scibx.2012.959 Rodent studies suggest inhibiting NP1 could help treat neuropathic pain. Full Text | PDF
Ryanodine receptor 2 (RyR2) doi:10.1038/scibx.2012.960 Mouse studies suggest stabilizing RyR2 could help prevent post-traumatic stress disorder. Full Text | PDF
VEGF-A doi:10.1038/scibx.2012.961 An in vitro study identified an antagonist of VEGF-A that could be useful for treating AMD. The d-stereoisomer of VEGF-A was synthesized and used to screen for d-protein ligands of VEGF-A. Full Text | PDF
Class A β-lactamase (blaC)-specific detection of Mycobacterium tuberculosis doi:10.1038/scibx.2012.962 Fluorescent probes specific for M. tuberculosis blaC could be useful for detecting M. tuberculosis in clinical samples. Full Text | PDF
Human blood metabolite–based timetable doi:10.1038/scibx.2012.963 A human blood metabolite–based timetable could help estimate internal body time with just two blood samples. Full Text | PDF
Mass spectrometric, antibody-free quantification of proteins in biofluids doi:10.1038/scibx.2012.964 A mass spectrometry–based method could be useful for quantifying proteins in biofluids with ELISA-like sensitivity. Full Text | PDF
Conditional fukutin (Fktn) knockout mice as a model for secondary dystroglycanopathies doi:10.1038/scibx.2012.965 Conditional Fktn knockout mice could be useful models for secondary dystroglycanopathies, a family of muscular dystrophies caused by mutations in multiple glycosyltransferase genes. Full Text | PDF
Lipid nanoparticle formulation of self-amplifying RNAs for vaccination doi:10.1038/scibx.2012.966 Self-amplifying RNA presented in a lipid nanoparticle formulation could be a viable nonviral alternative to viral delivery–based RNA vaccination technologies. Full Text | PDF
Polyethylene glycol (PEG) coating to improve delivery of drug-loaded nanoparticles across the blood brain barrier (BBB) doi:10.1038/scibx.2012.967 Densely coating drug-loaded nanoparticles with PEG could help improve their delivery to the brain. Full Text | PDF
High throughput flow cytometry for small molecule screening doi:10.1038/scibx.2012.968 High throughput, multiplexed flow cytometry could provide a way to rapidly screen small molecules in immune cells. Full Text | PDF
Map of disease gene regulation by noncoding DNA doi:10.1038/scibx.2012.969 A genomic study identified noncoding DNA sequences that regulate the expression of disease-related genes and might provide targets that affect disease progression. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment